Targeting metabolic enzymes for cancer therapy can have significant implications, and the study suggests that HK3, an isoenzyme in the hexokinase family, plays a crucial role in the immune evasion of ccRCC cells by affecting the stability of the EP300 protein and, subsequently, the expression of PD-L1. The gene discussed is EP300; the disease is cancer.